S&P 500   3,964.65 (+0.78%)
DOW   33,847.29 (+0.74%)
QQQ   282.91 (+0.85%)
AAPL   142.34 (+0.99%)
MSFT   246.09 (+0.70%)
META   116.32 (+2.10%)
GOOGL   94.65 (-0.31%)
AMZN   90.28 (+2.06%)
TSLA   173.02 (-0.59%)
NVDA   163.72 (+1.56%)
NIO   13.32 (+5.88%)
BABA   93.62 (+5.99%)
AMD   70.26 (+0.17%)
T   19.38 (+0.41%)
MU   54.58 (+1.41%)
CGC   3.23 (-0.31%)
F   13.21 (+0.84%)
GE   85.50 (+0.59%)
DIS   93.18 (+1.12%)
AMC   6.50 (+7.44%)
PYPL   75.40 (+1.32%)
PFE   50.43 (+0.38%)
NFLX   310.52 (+0.68%)
S&P 500   3,964.65 (+0.78%)
DOW   33,847.29 (+0.74%)
QQQ   282.91 (+0.85%)
AAPL   142.34 (+0.99%)
MSFT   246.09 (+0.70%)
META   116.32 (+2.10%)
GOOGL   94.65 (-0.31%)
AMZN   90.28 (+2.06%)
TSLA   173.02 (-0.59%)
NVDA   163.72 (+1.56%)
NIO   13.32 (+5.88%)
BABA   93.62 (+5.99%)
AMD   70.26 (+0.17%)
T   19.38 (+0.41%)
MU   54.58 (+1.41%)
CGC   3.23 (-0.31%)
F   13.21 (+0.84%)
GE   85.50 (+0.59%)
DIS   93.18 (+1.12%)
AMC   6.50 (+7.44%)
PYPL   75.40 (+1.32%)
PFE   50.43 (+0.38%)
NFLX   310.52 (+0.68%)
S&P 500   3,964.65 (+0.78%)
DOW   33,847.29 (+0.74%)
QQQ   282.91 (+0.85%)
AAPL   142.34 (+0.99%)
MSFT   246.09 (+0.70%)
META   116.32 (+2.10%)
GOOGL   94.65 (-0.31%)
AMZN   90.28 (+2.06%)
TSLA   173.02 (-0.59%)
NVDA   163.72 (+1.56%)
NIO   13.32 (+5.88%)
BABA   93.62 (+5.99%)
AMD   70.26 (+0.17%)
T   19.38 (+0.41%)
MU   54.58 (+1.41%)
CGC   3.23 (-0.31%)
F   13.21 (+0.84%)
GE   85.50 (+0.59%)
DIS   93.18 (+1.12%)
AMC   6.50 (+7.44%)
PYPL   75.40 (+1.32%)
PFE   50.43 (+0.38%)
NFLX   310.52 (+0.68%)
S&P 500   3,964.65 (+0.78%)
DOW   33,847.29 (+0.74%)
QQQ   282.91 (+0.85%)
AAPL   142.34 (+0.99%)
MSFT   246.09 (+0.70%)
META   116.32 (+2.10%)
GOOGL   94.65 (-0.31%)
AMZN   90.28 (+2.06%)
TSLA   173.02 (-0.59%)
NVDA   163.72 (+1.56%)
NIO   13.32 (+5.88%)
BABA   93.62 (+5.99%)
AMD   70.26 (+0.17%)
T   19.38 (+0.41%)
MU   54.58 (+1.41%)
CGC   3.23 (-0.31%)
F   13.21 (+0.84%)
GE   85.50 (+0.59%)
DIS   93.18 (+1.12%)
AMC   6.50 (+7.44%)
PYPL   75.40 (+1.32%)
PFE   50.43 (+0.38%)
NFLX   310.52 (+0.68%)
OTCMKTS:NVZMY

Novozymes A/S - NVZMY Stock Forecast, Price & News

$60.44
+1.29 (+2.18%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$60.09
$61.14
50-Day Range
$47.06
$60.65
52-Week Range
$45.97
$83.31
Volume
11,677 shs
Average Volume
14,495 shs
Market Capitalization
$13.74 billion
P/E Ratio
32.68
Dividend Yield
0.92%
Price Target
$406.67

Novozymes A/S MarketRank™ Forecast

Analyst Rating
Hold
1.88 Rating Score
Upside/​Downside
572.8% Upside
$406.67 Price Target
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.53mentions of Novozymes A/S in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
1.75%
From $1.71 to $1.74 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

NVZMY stock logo

About Novozymes A/S (OTCMKTS:NVZMY) Stock

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Stock News Headlines

Analysts Set Novozymes A/S (OTCMKTS:NVZMY) Price Target at $406.67
Brokerages Set Novozymes A/S (OTCMKTS:NVZMY) PT at $406.67
NVZMY Novozymes A/S
Catalysing carbon emission cuts at UNGA
Here's what to expect from Novozymes A-S (B) Un's earnings
Novozymes A/S ADR - Stock Quote NVZMY
Novozymes A/S (NVZMY)
Group financial statement and annual report for 2021
CE or NVZMY: Which Is the Better Value Stock Right Now?
See More Headlines
Receive NVZMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMY Company Calendar

Last Earnings
4/29/2020
Today
12/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:NVZMY
Employees
6,527
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$406.67
High Stock Price Forecast
$490.00
Low Stock Price Forecast
$360.00
Forecasted Upside/Downside
+572.8%
Consensus Rating
Hold
Rating Score (0-4)
1.88
Research Coverage
8 Analysts

Profitability

Net Income
$500.53 million
Pretax Margin
24.04%

Debt

Sales & Book Value

Annual Sales
$2.38 billion
Cash Flow
$2.24 per share
Book Value
$8.51 per share

Miscellaneous

Free Float
N/A
Market Cap
$13.74 billion
Optionable
Not Optionable
Beta
0.68

Social Links


Key Executives

  • Ms. Ester Baiget (Age 51)
    Pres & CEO
    Comp: $2.14M
  • Mr. Lars Green M.Sc. (Age 55)
    MSc, Exec. VP & CFO
    Comp: $2.09M
  • Ms. Graziela Chaluppe dos Santos Malucelli (Age 49)
    COO and Exec. VP of Operations, Supply & Quality
  • Mr. Tobias Cornelius Bjorklund
    Head of Investor Relations
  • Mr. Tue Micheelsen
    VP of Global Sales & Marketing
  • Mr. Morten Enggaard Rasmussen (Age 46)
    Exec. VP of People, Sustainability & Brand
  • Mr. Pedro Luiz Fernandes
    Head of Corp. Affairs & Sustainability - Novozymes Latin America
  • Mr. Anders Lund (Age 49)
    Exec. VP of Consumer Biosolutions
  • Mr. Sebastian Søderberg
    VP and Head of New Bus. Devel. - Incubations & Acquisitions
  • Ms. Tina Sejersgaard Fanoe (Age 53)
    Exec. VP of Agriculture & Industrial Biosolutions













NVZMY Stock - Frequently Asked Questions

Should I buy or sell Novozymes A/S stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novozymes A/S in the last twelve months. There are currently 3 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVZMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVZMY, but not buy additional shares or sell existing shares.
View NVZMY analyst ratings
or view top-rated stocks.

What is Novozymes A/S's stock price forecast for 2023?

8 Wall Street analysts have issued 12-month price objectives for Novozymes A/S's stock. Their NVZMY share price forecasts range from $360.00 to $490.00. On average, they anticipate the company's stock price to reach $406.67 in the next twelve months. This suggests a possible upside of 572.8% from the stock's current price.
View analysts price targets for NVZMY
or view top-rated stocks among Wall Street analysts.

How have NVZMY shares performed in 2022?

Novozymes A/S's stock was trading at $83.12 at the beginning of 2022. Since then, NVZMY stock has decreased by 27.3% and is now trading at $60.44.
View the best growth stocks for 2022 here
.

Are investors shorting Novozymes A/S?

Novozymes A/S saw a increase in short interest in October. As of October 31st, there was short interest totaling 1,200 shares, an increase of 100.0% from the October 15th total of 600 shares. Based on an average daily volume of 38,700 shares, the short-interest ratio is currently 0.0 days.
View Novozymes A/S's Short Interest
.

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMY) posted its earnings results on Wednesday, April, 29th. The biotechnology company reported $0.42 earnings per share for the quarter, hitting the consensus estimate of $0.42. The biotechnology company earned $558.75 million during the quarter. Novozymes A/S had a net margin of 20.08% and a trailing twelve-month return on equity of 27.21%.

How often does Novozymes A/S pay dividends? What is the dividend yield for Novozymes A/S?

Novozymes A/S declared a dividend on Tuesday, March 15th. Shareholders of record on Friday, March 18th will be paid a dividend of $0.567 per share on Tuesday, April 5th. This represents a yield of 0.95%. The ex-dividend date is Thursday, March 17th.
Read our dividend analysis for NVZMY
.

Is Novozymes A/S a good dividend stock?

Novozymes A/S (OTCMKTS:NVZMY) pays an annual dividend of $0.55 per share and currently has a dividend yield of 0.92%.
Read our dividend analysis for NVZMY.

What is Novozymes A/S's stock symbol?

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMY."

How do I buy shares of Novozymes A/S?

Shares of NVZMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novozymes A/S's stock price today?

One share of NVZMY stock can currently be purchased for approximately $60.44.

How much money does Novozymes A/S make?

Novozymes A/S (OTCMKTS:NVZMY) has a market capitalization of $13.74 billion and generates $2.38 billion in revenue each year.

How many employees does Novozymes A/S have?

The company employs 6,527 workers across the globe.

Does Novozymes A/S have any subsidiaries?
The following companies are subsidiares of Novozymes A/S: Allopartis, Beta Renewables S.p.A., Delta Biotechnology, Earth BioSciences, Grundejerforeningen Hallas Park, Grundejerforeningen Smørmosen, Iogen Bio-Products, MagnaBioAnalytics LLC, Microbiogen PTY Ltd., Natural Industries, Novozymes (China) Biotechnology Co. Ltd., Novozymes (China) Investment Co. Ltd., Novozymes (Shenyang) Biologicals Co. Ltd., Novozymes (Thailand) Limited, Novozymes Australia Pty. Ltd., Novozymes Belgium BVBA, Novozymes BioAg A/S, Novozymes BioAg Inc., Novozymes BioAg Limited, Novozymes BioAg Productos Para Agricultura Ltda., Novozymes BioAg S.A., Novozymes Bioindustrial A/S, Novozymes Bioindustrial China A/S, Novozymes Biologicals Inc., Novozymes Biopharma DK A/S, Novozymes Blair Inc., Novozymes Canada Limited, Novozymes Deutschland GmbH, Novozymes Enzim Dis Ticaret Ltd., Novozymes France S.A.S, Novozymes Hong Kong Ltd., Novozymes Inc., Novozymes Italia S.r.l., Novozymes Japan Ltd., Novozymes Korea Limited, Novozymes Latin America Ltda., Novozymes Malaysia Sdn. Bhd., Novozymes Mexicana S.A. de C.V., Novozymes Mexico S.A. de C.V., Novozymes Nederland B.V., Novozymes North America Inc., Novozymes RUS LLC, Novozymes Singapore Pte. Ltd., Novozymes South Africa (Pty) Ltd., Novozymes South Asia Pvt. Ltd., Novozymes Spain S.A., Novozymes Sweden AB, Novozymes Switzerland AG, Novozymes Switzerland Holding AG, Novozymes UK Ltd, Novozymes US Inc., OrganoBalance GmbH, Pacific Vet Group-USA, Philom Bios, PrecisionBiotics Group Limited, Qingdao Huayuan Fine Bio-Products, Suzhou Hongda Enzyme Co. Ltd., Sybron Biochemicals, TJ Technologies, and Turfal Indústria e Comércio de Produtos Agrônomicos e Biológicos.
Read More
How can I contact Novozymes A/S?

Novozymes A/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The official website for the company is www.novozymes.com. The biotechnology company can be reached via phone at (454) 446-0000, via email at novozymesir@novozymes.com, or via fax at 45-4446-9999.

This page (OTCMKTS:NVZMY) was last updated on 12/8/2022 by MarketBeat.com Staff